Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)

Award Number: R43AG063652
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/15/2019
PERIOD OF PERFORMANCE END DATE: 08/31/2020

Group Awards By:

View Award Description

Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID) - A growing body of evidence indicates that decreased brain blood flow, increased reactive oxygen (ROS) and pro-inflammatory mechanisms accelerate the progression of neurodegenerative diseases such as Alzheimer’s Disease and Related Dementias (ADRD) including Vascular Contributions to Cognitive Impairment (VCID) (1), (3),(5),(6), (8). In older adults, inflammatory related diseases, such as cardiac disease or heart failure that lead to decreased brain perfusion and increased brain and systemic inflammation, are known to increase the risk for dementia and the development of ADRD and VCID (9),(10),(11),(12). ProNeurogen has been working with our University of Arizona collaborators to develop novel Angiotensin 1-7 (Ang-1–7) formulations to treat inflammation-related cognitive impairment in heart disease patients at for risk ADRD and VCID. These novel peptide formulations are designed to act on Mas receptors (MasR) within the brain vascular endothelium and neuronal cells to decrease brain ROS production, neuroinflammation and improve cerebral vascular blood flow. We have begun to translate these preclinical findings into novel peptide therapeutics to treat inflammation related cognitive impairment in patients with heart disease who are at risk for ADRD or VCID. We have an approved FDA IND # 125320 and support for Phase 2a trials for native Ang-(1-7) for treatment of cognitive impairment in heart failure (HF) patients and NIH support for our trial in cardiac bypass surgery patients (CABG). We are currently enrolling in these studies. Our current approved treatment protocol is once a day, subcutaneous 100 microg/kg injection using a standard needle and syringe for 85 days in our HF patients. However, in order to increase patient compliance and comfort with injections as well as accelerate commercialization we are currently investigating new formulations and injection methods that are more patient friendly and easier to administer. The goal of the present Phase I project is to begin development of a microneedle injection platform for the administration of our novel peptide therapies for treating brain inflammation related cognitive impairment. We will begin feasibility studies with the 3M Drug Delivery Systems to develop a microneedle injection platform for our Ang-(1-7) peptides. We will take advantage of 3M’s extensive experience in transdermal manufacturing expertise to complete the 2 principal objectives of this project: 1. Objective 1. Complete in vitro physiochemical analysis of loading and ejecting 10mg/ml Ang (1-7) peptides with the 3M Hollow Microstructured Transdermal System (hMTS). 2. Objective 2. Complete a PK study of Ang (1-7) peptides comparing 3M hMTS to subcutaneous injections in swine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	PRONEUROGEN, INC.	1970 WENTWORTH RD	TUCSON	AZ	85749	PIMA	USA	Aging Research	000	1	3/12/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	PRONEUROGEN, INC.	1970 WENTWORTH RD	TUCSON	AZ	85749	PIMA	USA	Aging Research	000	1	4/30/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $405,415 )
2019	2019	PRONEUROGEN, INC.	1970 WENTWORTH RD	TUCSON	AZ	85749	PIMA	USA	Aging Research	000	1	6/13/2019	NEW	$222,855
2019	2019	PRONEUROGEN, INC.	1970 WENTWORTH RD	TUCSON	AZ	85749	PIMA	USA	Aging Research	001	1	8/29/2019	SUPPLEMENT FOR EXPANSION	$182,560
														Subtotal = $405,415

Grand Total All Awards = $405,415

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Microneedle Formulation for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease Related Dementia (ADRD) and Vascular Contributions to Cognitive Impairment and Dementia (VCID)

Award Number: R43AG063652

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/15/2019

PERIOD OF PERFORMANCE END DATE: 08/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer